Several institutional investors have increased their shares in Kenvue. Vanguard raised its stake by 12%, owning 166.8 million shares valued at $3.58 billion. Price T Rowe Associates boosted its holdings by 23.1%, now holding 134.6 million shares worth $2.89 billion. Massachusetts Financial Services increased its shares by 9.6% to 79.9 million, worth $1.45 billion. Wellington Management raised its stake by 6.7% to 76.5 million shares valued at $1.65 billion. JPMorgan also increased its shares by 11.1%, now owning 68.3 million worth $1.47 billion. In total, 97.64% of Kenvues stock is held by institutional investors.
Kenvue Shares Down 0.7%
Kenvue shares opened at $22.63 on Thursday. The stock’s 52-week range is $17.67 to $23.55. Financial metrics include a quick ratio of 0.68, current ratio of 0.99, and debt-to-equity ratio of 0.69. The market cap is $43.33 billion with a PE ratio of 29.01 and a beta of 1.40.
Kenvue reported earnings on August 6th. The company had an EPS of $0.32, exceeding expectations of $0.28. Revenue for the quarter was $4 billion, above the forecast of $3.93 billion, though down 0.3% year-over-year. Analysts predict an EPS of 1.08 for the current fiscal year.
Kenvue Increases Dividend
Kenvue recently declared a quarterly dividend of $0.205 per share, up from $0.20, paid on August 28th. The dividend yield is 3.62%, with an annualized dividend of $0.82, and a payout ratio of 105.13%.
Analysts Set New Price Targets
Analysts have adjusted price targets for Kenvue. Piper Sandler increased their target from $20.00 to $21.00. Deutsche Bank raised its target from $23.00 to $24.00. Citigroup reduced its target from $21.00 to $20.00. UBS raised their target from $20.00 to $22.00, while Royal Bank of Canada lowered their assessment from outperform to sector perform with a $24.00 target. Currently, the stock has an average rating of Hold with a consensus price target of $22.10.
View Our Latest Report on Kenvue
Kenvue Profile
Kenvue Inc is a health-focused consumer company operating globally across three segments: Self Care, Skin Health and Beauty, and Essential Health. Their products include well-known brands like Tylenol, Motrin, Benadryl, and Zyrtec.
Featured Stories
- Five stocks we like better than Kenvue
- Investing in Tech Stocks
- S&P 500 Resistance: Best Upside Stocks
- Understanding Downgrades in Investing
- Nike’s Earnings Drop: Buying Opportunity
- Best Aerospace Stocks
- Microsoft’s Targeted Upside Opportunity
Receive Daily News & Ratings for Kenvue – Enter your email below for a free daily summary of Kenvue news and analyst ratings with MarketBeat.com’s FREE daily newsletter.
`
